Clinical Trial Update: 68Ga-NTA-476 Imaging in Prostate Cancer [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating the 68Ga-NTA-476 imaging agent for detecting prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-NTA-476

Snippet

Sponsor: Melbourne Theranostic Innovation Centre | Conditions: Prostate Cancer | EARLY_Phase 1 | Status: COMPLETED